| Bioactivity | SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7[1]. | ||||||||||||
| Target | pKi: 7.7 (NMDA receptor) | ||||||||||||
| In Vivo | SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action[1]. Animal Model: | ||||||||||||
| Name | SDZ 220-581 | ||||||||||||
| CAS | 174575-17-8 | ||||||||||||
| Formula | C16H17ClNO5P | ||||||||||||
| Molar Mass | 369.74 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Urwyler S, Campbell E, Fricker G, Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):65 [2]. Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. |